title: Xanthine oxidase inhibitors in heart failure: where do we go from here?
authors.affiliation: From Department of Medicine (L.T., J.M.H.) and Interdisciplinary Stem Cell Institute (J.M.H.), University of Miami Miller School of Medicine, FL; and Veterans Affairs Medical Center, Miami, FL (L.T.).
authors.forename: Leonardo
authors.initials: L
authors.lastname: Tamariz
authors.affiliation: From Department of Medicine (L.T., J.M.H.) and Interdisciplinary Stem Cell Institute (J.M.H.), University of Miami Miller School of Medicine, FL; and Veterans Affairs Medical Center, Miami, FL (L.T.). jhare@med.miami.edu.
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Hare
mesh_terms: D000493:Allopurinol / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy*; D008297:Male; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
chemical_list: D000493:Allopurinol; D014969:Xanthine Oxidase
keywords: Editorials; antagonists and inhibitors; heart failure; nitric oxide; uric acid; xanthine oxidase